- Home
- HOOK vs PTN Comparison
HOOK vs PTN Comparison
Compare HOOK & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- PTN
- Stock Information
- Founded
- HOOK 2011
- PTN 1986
- Country
- HOOK United States
- PTN United States
- Employees
- HOOK N/A
- PTN N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- HOOK Health Care
- PTN Health Care
- Exchange
- HOOK Nasdaq
- PTN Nasdaq
- Market Cap
- HOOK 30.2M
- PTN 25.4M
- IPO Year
- HOOK 2019
- PTN 1993
- Fundamental
- Price
- HOOK $2.80
- PTN $0.97
- Analyst Decision
- HOOK Strong Buy
- PTN Strong Buy
- Analyst Count
- HOOK 4
- PTN 1
- Target Price
- HOOK $38.75
- PTN $17.00
- AVG Volume (30 Days)
- HOOK 53.3K
- PTN 258.0K
- Earning Date
- HOOK 11-22-2024
- PTN 11-14-2024
- Dividend Yield
- HOOK N/A
- PTN N/A
- EPS Growth
- HOOK N/A
- PTN N/A
- EPS
- HOOK N/A
- PTN N/A
- Revenue
- HOOK $49,999,000.00
- PTN $2,384,113.00
- Revenue This Year
- HOOK $155.36
- PTN N/A
- Revenue Next Year
- HOOK N/A
- PTN N/A
- P/E Ratio
- HOOK N/A
- PTN N/A
- Revenue Growth
- HOOK 227.80
- PTN N/A
- 52 Week Low
- HOOK $2.76
- PTN $0.68
- 52 Week High
- HOOK $11.30
- PTN $5.65
- Technical
- Relative Strength Index (RSI)
- HOOK 21.10
- PTN 40.42
- Support Level
- HOOK $3.58
- PTN $1.06
- Resistance Level
- HOOK $3.84
- PTN $1.26
- Average True Range (ATR)
- HOOK 0.26
- PTN 0.14
- MACD
- HOOK -0.08
- PTN -0.02
- Stochastic Oscillator
- HOOK 2.96
- PTN 10.97
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.